Entrada Therapeutics (TRDA) Amortizatization of Intangibles (2022 - 2026)
Entrada Therapeutics (TRDA) posted quarterly Amortizatization of Intangibles of $548000.0 for Q1 2026, down 59.04% year-over-year from $1.3 million in Q1 2025, and down 13.43% quarter-over-quarter from $633000.0 in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Entrada Therapeutics' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $548000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 59.04% year-over-year to $548000.0; the TTM figure through Mar 2026 stood at $2.9 million (down 69.08% YoY), while the FY2025 annual figure was $3.7 million, down 63.36% from the prior year.
- Amortizatization of Intangibles for Q1 2026 stood at $548000.0, down from $633000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $3.2 million in Q3 2024, with the low at -$145000.0 in Q2 2022.
- The 5-year median for Amortizatization of Intangibles is $961000.0 (2025), against an average of $1.2 million.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles jumped 5687.5% in 2023, then tumbled 77.0% in 2025.
- Entrada Therapeutics' Amortizatization of Intangibles stood at $104000.0 in 2022, then surged by 1822.12% to $2.0 million in 2023, then gained by 25.41% to $2.5 million in 2024, then sank by 74.75% to $633000.0 in 2025, then dropped by 13.43% to $548000.0 in 2026.
- Business Quant data shows TRDA's Amortizatization of Intangibles at $548000.0 in Q1 2026, $633000.0 in Q4 2025, and $739000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Entrada Therapeutics | 297.03 Mn | 297.03 Mn | - | 450,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 450,000.00 |
| Mar 31, 2026 | 548,000.00 |
| Dec 31, 2025 | 633,000.00 |
| Sep 30, 2025 | 739,000.00 |
| Jun 30, 2025 | 961,000.00 |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 2.51 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 1.69 Mn |
| Mar 31, 2023 | 237,000.00 |
| Dec 31, 2022 | 104,000.00 |
| Sep 30, 2022 | 32,000.00 |
| Jun 30, 2022 | -145,000.00 |
| Mar 31, 2022 | -142,000.00 |